Masitinib Studies Suspended Over Ischemic Heart Disease Risk
https://pixabay.com/en/anatomy-human-heart-pulse-frequency-2328534/

Masitinib Studies Suspended Over Ischemic Heart Disease Risk

Altogether, AB Science has been evaluating a tyrosine kinase inhibitor, masitinib, for a variety of conditions including amyotrophic lateral sclerosis (ALS), COVID-19, and mastocytosis. But according to ALS News Today,…

Continue Reading Masitinib Studies Suspended Over Ischemic Heart Disease Risk
Ayvakit for Gastrointestinal Stromal Tumors Approved in China
source: pixabay.com

Ayvakit for Gastrointestinal Stromal Tumors Approved in China

According to a story from Markets Insider, the biopharmaceutical company CStone Pharmaceuticals has announced that China's National Medical Products Administration (NMPA) has approved avapritinib (marketed as Ayvakit) as a treatment…

Continue Reading Ayvakit for Gastrointestinal Stromal Tumors Approved in China

Finding an Effective Personalized Therapy for Mastocytosis can be Frustrating, but it is Possible

What Exactly is Mast Cell Disease According to The Mastocytosis Society (TMS), there are three forms of mast cell disease. All involve the malfunction or over-development of mast cells in…

Continue Reading Finding an Effective Personalized Therapy for Mastocytosis can be Frustrating, but it is Possible

New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!

GT Biopharma has just announced that their Phase 1 clinical trial for Mastocytosis, Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML) has been authorized to begin. Although this investigation had previously…

Continue Reading New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!
Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says
Katzenfee50 / Pixabay

Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says

According to a story from Cure Today, a recent study has found that identifying mutations in patients with myeloproliferative neoplasms may be the key in predicting outcomes, such as disease…

Continue Reading Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says
Raising a Son While Managing POTS, EDS, and Gastroparesis: Lindsay’s Story
Photo courtesy of Lindsay Fogarty

Raising a Son While Managing POTS, EDS, and Gastroparesis: Lindsay’s Story

My name is Lindsay Fogarty. I am a 25-year-old single mother to a wonderful 6, almost 7-year-old son, named Andrew. As I am writing this I am listening to the…

Continue Reading Raising a Son While Managing POTS, EDS, and Gastroparesis: Lindsay’s Story